Evidence map›Paper›PMID 34643251›Full record

ArticleInternational journal of molecular medicine2021

Clarifying the molecular mechanism of tomentosin‑induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis.

Patrizia Virdis, Rossana Migheli, Valentina Bordoni, Francesco Paolo Fiorentino, Luca Sanna, Irene Marchesi, Giorgio Pintore, Grazia Galleri, Maria Rosaria Muroni, Luigi Bagella and 3 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Patrizia Virdis *Department of Medical, Surgical and Experimental Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Rossana Migheli *Department of Medical, Surgical and Experimental Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Valentina BordoniDepartment of Biomedical Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Francesco Paolo FiorentinoKitos Biotech Srls, Porto Conte Ricerche, I‑07100 Sassari, Sardinia, Italy.
Luca SannaDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Irene MarchesiKitos Biotech Srls, Porto Conte Ricerche, I‑07100 Sassari, Sardinia, Italy.
Giorgio PintoreDepartment of Chemistry and Pharmacy, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Grazia GalleriDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Maria Rosaria MuroniDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Luigi BagellaDepartment of Biomedical Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Claudio FozzaDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Maria Rosaria De MiglioDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
Luigi PoddaDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, I‑07100 Sassari, Sardinia, Italy.
University of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is an aggressive B cell malignancy. Substantial progress has been made in the therapeutic context for patients with MM, however it still represents an incurable disease due to drug resistance and recurrence. Development of more effective or synergistic therapeutic approaches undoubtedly represents an unmet clinical need. Tomentosin is a bioactive natural sesquiterpene lactone extracted by various plants with therapeutic properties, including anti‑neoplastic effects. In the present study, the potential antitumor activity of tomentosin was evaluated on the human RPMI‑8226 cell line, treated with increasing tomentosin concentration for cytotoxicity screening. The data suggested that both cell cycle arrest and cell apoptosis could explain the antiproliferative effects of tomentosin and may result in the inhibition of RPMI‑8226 cell viability. To assess differentially expressed genes contributing to tomentosin activity and identify its mechanism of action, a microarray gene expression profile was performed, identifying 126 genes deregulated by tomentosin. To address the systems biology and identify how tomentosin deregulates gene expression in MM from a systems perspective, all deregulated genes were submitted to enrichment and molecular network analysis. The Protein‑Protein Interaction (PPI) network analysis showed that tomentosin in human MM induced the downregulation of genes involved in several pathways known to lead immune‑system processes, such as cytokine‑cytokine receptor interaction, chemokine or NF‑κB signaling pathway, as well as genes involved in pathways playing a central role in cellular neoplastic processes, such as growth, proliferation, migration, invasion and apoptosis. Tomentosin also induced endoplasmic reticulum stress via upregulation of cyclic AMP‑dependent transcription factor ATF‑4 and DNA damage‑inducible transcript 3 protein genes, suggesting that in the presence of tomentosin the protective unfolded protein response signaling may induce cell apoptosis. The functional connections analysis executed using the Connectivity Map tool, suggested that the effects of tomentosin on RPMI‑8226 cells might be similar to those exerted by heat shock proteins inhibitors. Taken together, these data suggested that tomentosin may be a potential drug candidate for the treatment of MM.

Indexed as

Antineoplastic Agents, PhytogenicApoptosisCell CycleCell Line, TumorDrug Screening Assays, AntitumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLactonesMultiple MyelomaProtein Interaction MapsSesquiterpenesAntineoplastic Agents, PhytogenicLactonesSesquiterpenestomentosinapoptosiscyclic AMP‑dependent transcription factor ATF‑4cytotoxicityDNA damage‑inducible transcript 3 proteingene expression profilingmultiple myelomaProtein‑Protein Interaction networktomentosin

Identifiers

PMID34643251
PMCPMC8522960
OpenAlexW3205671281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.